TY - JOUR
T1 - Management of pediatric central nervous system demyelinating disorders
T2 - Consensus of United States neurologists
AU - Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society
AU - Waldman, Amy T.
AU - Gorman, Mark P.
AU - Rensel, Mary R.
AU - Austin, Tracy E.
AU - Hertz, Deborah P.
AU - Kuntz, Nancy L.
AU - Acsadi, G.
AU - Alper, G.
AU - Bashir, K.
AU - Bass, N.
AU - Belman, A.
AU - Chabas, D.
AU - Chitnis, T.
AU - Cohen, M.
AU - Corboy, J.
AU - Fernandez, A.
AU - Fleming, J.
AU - Frohman, E.
AU - Giesser, B.
AU - Hahn, J.
AU - Islam, M.
AU - Kantor, D.
AU - Kaufman, M.
AU - Krupp, L.
AU - Lloyd, M.
AU - Lotze, T.
AU - Lucas, S.
AU - Mar, S.
AU - Mattson, D.
AU - Michelson, D.
AU - Mitchell, W.
AU - Moodley, M.
AU - Moses, H.
AU - Ness, J.
AU - Parker, C.
AU - Rodriguez, M.
AU - Rose, J.
AU - Rubin, J.
AU - Strober, J.
AU - Vanderver, A.
AU - Weinstock-Guttman, B.
AU - Weissman, B.
AU - Wollack, J.
AU - Yeh, A.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.
AB - Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.
KW - acute disseminated encephalomyelitis
KW - multiple sclerosis
KW - optic neuritis
UR - http://www.scopus.com/inward/record.url?scp=79957591907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957591907&partnerID=8YFLogxK
U2 - 10.1177/0883073810395141
DO - 10.1177/0883073810395141
M3 - Article
C2 - 21518802
AN - SCOPUS:79957591907
SN - 0883-0738
VL - 26
SP - 675
EP - 682
JO - Journal of child neurology
JF - Journal of child neurology
IS - 6
ER -